Bladder Cancer detection by urinary methylation markers GHSR/MAL: a validation study
World Journal of Urology · 16.10.2024 · 42 (1)
DOI: 10.1007/s00345-024-05287-5 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift World Journal of Urology, online erschienen am 16.10.2024. Verfasst von I J Beijert und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, DNA Methylation, Biomarkers, Tumor. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Although cystoscopy is a reliable tool for detecting bladder cancer, it poses a high burden on patients and entails high costs. This highlights the need for non-invasive and cost-effective alternatives. This study aimed to validate a previously developed urinary methylation marker panel containing GHSR and MAL .
Methods
We enrolled 134 patients who underwent cystoscopy because of hematuria, including 63 individuals with primary bladder cancer and 71 with non-malignant findings. Urine samples were self-collected at home and sent via regular mail. Subsequently, DNA was extracted and the hypermethylation of GHSR and MAL was evaluated using quantitative methylation-specific polymerase chain reaction. The performance of methylation markers was assessed using area-under-the-curve (AUC) analysis and sensitivity and specificity based on pre-established cut-off values.
Results
Validation of the marker panel GHSR/MAL resulted in an AUC of 0.87 at 79% sensitivity and 80% specificity. Sensitivity was comparable to the previous investigation ( P > 0.9), though specificity was significantly lower ( P = 0.026). Sensitivity was higher for high-grade tumors compared to low-grade tumors (94% vs. 60%, P = 0.002).
Conclusion
Validation of the GHSR/MAL methylation marker panel on at home collected urine samples confirms its robust performance for bladder cancer detection in a hematuria population, and underscores the diagnostic potential for future clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Department of Urology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
- Department of Urology, OLVG, Amsterdam, The Netherlands.
- Department of Epidemiology and Data Science, Amsterdam UMC, location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. r.steenbergen@amsterdamumc.nl.
Zitieren
APA
Beijert, I. J., van den Burgt, Y., Hentschel, A. E., Bosschieter, J., Kauer, P. C., Lissenberg-Witte, B. I., van Moorselaar, R. J. A., Nieuwenhuijzen, J. A., & Steenbergen, R. D. M. (2024). Bladder Cancer detection by urinary methylation markers GHSR/MAL: a validation study. World Journal of Urology, 42(1). https://doi.org/10.1007/s00345-024-05287-5
Vancouver
Beijert IJ, van den Burgt Y, Hentschel AE, Bosschieter J, Kauer PC, Lissenberg-Witte BI, et al. Bladder Cancer detection by urinary methylation markers GHSR/MAL: a validation study. World Journal of Urology. 2024;42(1). doi:10.1007/s00345-024-05287-5
BibTeX
@article{Beijert2024,
author = {Beijert, I J and van den Burgt, Y and Hentschel, A E and Bosschieter, J and Kauer, P C and Lissenberg-Witte, B I and van Moorselaar, R J A and Nieuwenhuijzen, J A and Steenbergen, R D M},
title = {Bladder Cancer detection by urinary methylation markers GHSR/MAL: a validation study},
journal = {World Journal of Urology},
year = {2024},
volume = {42},
number = {1},
doi = {10.1007/s00345-024-05287-5}
}
EUVIMED